Stockscreener 앱 받기
0.7301
1.07%
-0.0079
시간 외 거래:
.74
0.0099
+1.36%
Scynexis Inc 주식(SCYX)의 최신 뉴스
What catalysts could drive SCYNEXIS Inc. stock higher in 2025Achieve consistent profits with expert advice - jammulinksnews.com
How strong is SCYNEXIS Inc. company’s balance sheetAchieve breakthrough results with expert guidance - jammulinksnews.com
What are SCYNEXIS Inc. company’s key revenue driversRecord-breaking gains - jammulinksnews.com
SCYNEXIS Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingFree Stock Investment Discussion Area - Newser
Why SCYNEXIS Inc. stock attracts strong analyst attentionFree Stock Tips Group - Newser
What analysts say about SCYNEXIS Inc. stockSkyrocketing returns - Autocar Professional
Is SCYNEXIS Inc. a good long term investmentTremendous growth opportunities - Autocar Professional
What drives SCYNEXIS Inc. stock priceFastest return on investment - Autocar Professional
SCYNEXIS Inc. Stock Analysis and ForecastFast-track wealth growth - Autocar Professional
Is ATH.PRA a good long term investmentSkyrocketing returns - Jammu Links News
What makes SCYNEXIS Inc. stock price move sharplyTop Analyst Picks - Newser
How SCYNEXIS Inc. stock performs during market volatilityFree Stock Market Analysis Courses - Newser
Scynexis Inc (SCYX) Stock: A Year of Highs and Lows in the Market - investchronicle.com
SCYNEXIS Holds Annual Meeting, Re-elects Directors - The Globe and Mail
SCYNEXIS Faces Nasdaq Delisting Notice for Stock Price - TipRanks
Millennium Management LLC Takes Position in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World
Squarepoint Ops LLC Takes Position in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World
Jane Street Group LLC Buys New Holdings in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) & SCYNEXIS (NASDAQ:SCYX) Head-To-Head Survey - Defense World
Biosergen taps antifungal expert as board member - Biostock
Northern Trust Corp Has $186,000 Stake in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World
Scynexis resumes dosing in Phase III MARIO study after lengthy delay - MSN
SCYNEXIS resumes Phase 3 antifungal study after FDA lift By Investing.com - Investing.com South Africa
SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold - Insider Monkey
Scynexis resumes patient dosing in Phase 3 MARIO study - TipRanks
SCYNEXIS Resumes Patient Dosing In Phase 3 MARIO Study - marketscreener.com
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study | SCYX St - GuruFocus
2.82%
0.27%
자본화:
|
볼륨(24시간):